This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Ebola	T cell immunoglobulin and mucin domain 1 (HAVCR1; TIM-1)	<p><i>In vitro</i> studies suggest blocking TIM-1 could help treat Ebola and Marburg virus infection. In nonhuman primate cell cultures, small interfering RNA-mediated silencing of TIM-1 decreased susceptibility to infection by Ebola virus glycoprotein compared with silencing of a control protein. In human cell culture, a TIM-1 antibody decreased infection mediated by Ebola or Marburg virus glycoproteins compared with IgG control. Next steps could include testing the antibodies in animal models of infection.</p> <p>Celldex Therapeutics Inc.'s CDX-014, an antibody against TIM-1, is in preclinical testing to treat ovarian cancer.</p> <p>SciBX 4(20); doi:10.1038/scibx.2011.573 Published online May 19, 2011</p>	Patent and licensing status unavailable	<p>Kondratowicz, A.S. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online May 2, 2011; doi:10.1073/pnas.1019030108</p> <p>Contact: Wendy Maury, The University of Iowa, Iowa City, Iowa e-mail: wendy-maury@uiowa.edu</p>